Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545631 | 0.72 | L3MBTL1 (0.41) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL545682 | 0.71 | KMT2A (0.34) | SIGMAR1CYP2C19MEN1KMT2A | |
| SCHEMBL14284291 | 0.71 | CYP3A4 (0.38) | SIGMAR1CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL14284293 | 0.70 | CYP3A4 (0.32) | SIGMAR1HTT | |
| SCHEMBL10071225 | 0.68 | KDM1A (0.50) | CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL10073905 | 0.68 | CTSS (0.41) | SLC18A2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18695808 | 0.66 | SLC18A2 (0.40) | SLC18A2 | |
| SCHEMBL23809773 | 0.65 | CARM1 (0.45) | SLC18A2 | |
| SCHEMBL16158893 | 0.65 | CYP19A1 (0.40) | SLC18A2 | |
| SCHEMBL27583120 | 0.64 | ALDH1A1 (0.65) | SIGMAR1CYP2C19MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | PPOX, IDH3A, HMOX2 | SLC18A2 1392/4885SIGMAR1 1555/4885CYP2C19 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.